According to recent reports, Eli Lilly’s promising Alzheimer’s treatment, donanemab, may be blocked for use by Britain’s National Health Service (NHS). The
According to recent reports, Eli Lilly’s promising Alzheimer’s treatment, donanemab, may be blocked for use by Britain’s National Health Service (NHS). The